Learn to Customize Your Own Options Trading Strategy
This guide will help you evaluate and analyze your trading plan to create a custom options trading strategy tailored to your risk profile and market outlook. Learn how to take your trading to the next level.
Download your FREE Options Strategy Guide Today!
Rafael Amado, insider at Allogene Therapeutics
Rafael Amado Insider Alerts

Get notified the next time Rafael Amado buys or sells Allogene Therapeutics stock. Enter your email address below to get our daily insider buying and selling report.

Rafael Amado Insider Information

Rafael G. Amado, MD, is the Executive Vice President of Research and Development and Chief Medical Officer of Allogene. Rafael has over 15 years of biotechnology and pharmaceutical industry experience leading clinical and research teams. He most recently served as President of R&D, after serving as Chief Medical Officer, at Adaptimmune. Previously, he held several roles of increasing responsibility at GSK, most recently as Senior Vice President and Head of Oncology R&D. Prior to GSK, Rafael served as Executive Director of Therapeutic Oncology at Amgen, where he was responsible for worldwide clinical research strategy and execution and oversaw development activities for several investigational agents for molecularly characterized tumors. Before joining Amgen, he was on the faculty at the University of California, Los Angeles, most recently serving as Assistant Clinical Professor, Department of Medicine, Division of Hematology/Oncology. Rafael received an MD from the University of Seville School of Medicine and completed his internship and residency in internal medicine at Michael Reese Hospital and Medical Center, a University of Chicago-affiliated hospital. He completed a fellowship in hematology/oncology at the University of California, Los Angeles.

What is Rafael Amado's net worth?

The estimated net worth of Rafael Amado is at least $1.97 million as of October 7th, 2020. Dr. Amado owns 111,677 shares of Allogene Therapeutics stock worth more than $1,967,749 as of December 5th. This net worth approximation does not reflect any other investments that Dr. Amado may own. Learn More.

What is Rafael Amado's salary?

As the CMO of Allogene Therapeutics, Inc., Dr. Amado earned a total compensation package of $2,663,819.00 in 2020. Dr. Amado earned a salary of $510,000.00, a bonus of $75,000.00, stock awards of $561,176.00, options awards of $1,262,643.00, non-equity compensation of $255,000.00, and no other miscellaneous compensation.

How do I contact Rafael Amado?

The corporate mailing address for Dr. Amado and other Allogene Therapeutics executives is 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. Allogene Therapeutics can also be reached via phone at (650) 457-2700 and via email at [email protected]

Has Rafael Amado been buying or selling shares of Allogene Therapeutics?

During the last quarter, Rafael Amado has sold $280,195.00 in shares of Allogene Therapeutics stock. Most recently, Rafael Amado sold 11,507 shares of the business's stock in a transaction on Friday, October 1st. The shares were sold at an average price of $24.35, for a transaction totalling $280,195.45.

Who are Allogene Therapeutics' active insiders?

Allogene Therapeutics' insider roster includes Rafael Amado (CMO), Veer Bhavnagri (General Counsel), and Owen Witte (Director).

Are insiders buying or selling shares of Allogene Therapeutics?

During the last year, insiders at the sold shares 9 times. They sold a total of 76,476 shares worth more than $2,037,118.90. The most recent insider tranaction occured on October, 1st when CMO Rafael Amado sold 11,507 shares worth more than $280,195.45. Insiders at Allogene Therapeutics own 26.3 % of the company.

Information on this page was last updated on 10/1/2021.

Rafael Amado Insider Trading History at Allogene Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/1/2021Sell11,507$24.35$280,195.45View SEC Filing Icon  
10/7/2020Sell16,538$39.40$651,597.20111,677View SEC Filing Icon  
See Full Table

Rafael Amado Buying and Selling Activity at Allogene Therapeutics

This chart shows Rafael Amado's buying and selling at Allogene Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Allogene Therapeutics Company Overview

Allogene Therapeutics logo
Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, David M. Tanen, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.
Read More

Today's Range

Now: $17.62
Low: $17.39
High: $19.10

50 Day Range

MA: $18.93
Low: $13.13
High: $25.74

2 Week Range

Now: $17.62
Low: $12.90
High: $39.12

Volume

1,095,987 shs

Average Volume

979,769 shs

Market Capitalization

$2.51 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.77
Learn to Customize Your Own Options Trading Strategy
This guide will help you evaluate and analyze your trading plan to create a custom options trading strategy tailored to your risk profile and market outlook. Learn how to take your trading to the next level.
Download your FREE Options Strategy Guide Today!